학술논문
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Document Type
Article
Author
Source
In The Lancet Diabetes & Endocrinology May 2017 5(5):341-354
Subject
Language
ISSN
2213-8587